Non-Hodgkin Lymphoma Market - 2023-
Description
Non-Hodgkin Lymphoma Market Overview:
The Non-Hodgkin Lymphoma Market was valued at USD 7.3 billion in 2023 and is anticipated to reach by , at a CAGR of 0.082 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Non-Hodgkin Lymphoma Market.
This report delivers a comprehensive overview of the Non-Hodgkin Lymphoma Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non-Hodgkin Lymphoma Market. The Non-Hodgkin Lymphoma Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–.
Non-Hodgkin Lymphoma Market Scope:
By Disease Type
• B-cell Lymphomas
• T-cell Lymphoma
By Drug Class
• Monoclonal Antibodies
• Antibody-Drug Conjugates
• BTK/BCL-2 Kinase Inhibitors
• PI3 Kinase Inhibitors
• Protease Inhibitors
• PD1 Inhibitors
• Immunomodulatory Drugs
• Chemotherapy Agents
• CAR T-Cell Therapy
By Route of Administration
• Oral
• Parenteral
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Key Players
• AbbVie, Inc. (Pharmacyclics LLC)
• AstraZeneca plc
• Bayer AG
• Bristol-Myers Squibb Company (Celgene Corp.)
• Gilead Sciences, Inc. (Kite Pharma)
• Johnson & Johnson (Janssen Biotech, Inc.)
• Merck & Co., Inc.
• Novartis AG
• Roche Holding AG (F. Hoffmann-La Roche AG)
• Seagen, Inc. (Seattle Genetics, Inc.)
• Takeda Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.(LIST NOT EXHAUSTIVE)
Major Highlights
This report delivers a comprehensive overview of the Non-Hodgkin Lymphoma Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non-Hodgkin Lymphoma Market. The Non-Hodgkin Lymphoma Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.
Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
The Non-Hodgkin Lymphoma Market was valued at USD 7.3 billion in 2023 and is anticipated to reach by , at a CAGR of 0.082 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Non-Hodgkin Lymphoma Market.
This report delivers a comprehensive overview of the Non-Hodgkin Lymphoma Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non-Hodgkin Lymphoma Market. The Non-Hodgkin Lymphoma Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–.
Non-Hodgkin Lymphoma Market Scope:
By Disease Type
• B-cell Lymphomas
• T-cell Lymphoma
By Drug Class
• Monoclonal Antibodies
• Antibody-Drug Conjugates
• BTK/BCL-2 Kinase Inhibitors
• PI3 Kinase Inhibitors
• Protease Inhibitors
• PD1 Inhibitors
• Immunomodulatory Drugs
• Chemotherapy Agents
• CAR T-Cell Therapy
By Route of Administration
• Oral
• Parenteral
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Key Players
• AbbVie, Inc. (Pharmacyclics LLC)
• AstraZeneca plc
• Bayer AG
• Bristol-Myers Squibb Company (Celgene Corp.)
• Gilead Sciences, Inc. (Kite Pharma)
• Johnson & Johnson (Janssen Biotech, Inc.)
• Merck & Co., Inc.
• Novartis AG
• Roche Holding AG (F. Hoffmann-La Roche AG)
• Seagen, Inc. (Seattle Genetics, Inc.)
• Takeda Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.(LIST NOT EXHAUSTIVE)
Major Highlights
This report delivers a comprehensive overview of the Non-Hodgkin Lymphoma Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non-Hodgkin Lymphoma Market. The Non-Hodgkin Lymphoma Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.
Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
Table of Contents
217 Pages
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet by Disease Type
- 3.2. Snippet by Drug Class
- 3.3. Snippet by Route of Administration
- 3.4. Snippet by Distribution Channel
- 3.5. Snippet by Region
- 4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. The Growing Regulatory Approvals for Non-Hodgkin Lymphoma
- 4.1.1.2. The Increasing Clinical Trials for Non-Hodgkin Lymphoma Drugs
- 4.1.2. Restraints
- 4.1.2.1. Lack of Specific Targeted Therapies for Treating Non-Hodgkin Lymphoma
- 4.1.3. Opportunity
- 4.1.3.1. Exploring Combination Therapies for Enhanced Non-Hodgkin Lymphoma Treatment
- 4.1.4. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter’s 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Unmet Needs
- 5.4. Regulatory Analysis
- 6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers’ Strategic Initiatives
- 6.6. Conclusion
- 7. Russia-Ukraine War Analysis
- 8. By Disease Type
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 8.1.2. Market Attractiveness Index, By Disease Type
- 8.2. B-cell Lymphomas*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. T-cell Lymphoma
- 9. By Drug Class
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 9.1.2. Market Attractiveness Index, By Drug Class
- 9.2. Monoclonal Antibodies*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Antibody-Drug Conjugates
- 9.4. BTK/BCL-2 Kinase Inhibitors
- 9.5. PI3 Kinase Inhibitors
- 9.6. Protease Inhibitors
- 9.7. PD1 Inhibitors
- 9.8. Immunomodulatory Drugs
- 9.9. Chemotherapy Agents
- 9.10. CAR T-Cell Therapy
- 10. By Route of Administration
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.1.2. Market Attractiveness Index, By Route of Administration
- 10.2. Oral*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Parenteral
- 10.4. Others
- 11. By Distribution Channel
- 11.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.2. Market Attractiveness Index, By Distribution Channel
- 11.1. Hospital Pharmacies*
- 11.1.1. Introduction
- 11.1.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 11.2. Retail Pharmacies
- 11.3. Online Pharmacies
- 12. By Region
- 12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 12.1.2. Market Attractiveness Index, By Region
- 12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
- 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
- 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 12.2.7.1. The U.S.
- 12.2.7.2. Canada
- 12.2.7.3. Mexico
- 12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
- 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
- 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 12.3.7.1. Germany
- 12.3.7.2. The U.K.
- 12.3.7.3. France
- 12.3.7.4. Italy
- 12.3.7.5. Spain
- 12.3.7.6. Rest of Europe
- 12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
- 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
- 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 12.4.7.1. Brazil
- 12.4.7.2. Argentina
- 12.4.7.3. Rest of South America
- 12.5. Asia Pacific
- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
- 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
- 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 12.5.7.1. China
- 12.5.7.2. India
- 12.5.7.3. Japan
- 12.5.7.4. Australia
- 12.5.7.5. Rest of Asia Pacific
- 12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
- 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
- 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 13. Competitive Landscape
- 13.1. Competitive Scenario
- 13.2. Product Benchmarking
- 13.3. Company Share Analysis
- 13.4. Key Developments and Strategies
- 14. Company Profiles
- 14.1. AbbVie, Inc. (Pharmacyclics LLC) *
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Financial Overview
- 14.1.4. Key Developments
- 14.2. AstraZeneca plc
- 14.3. Bayer AG
- 14.4. Bristol-Myers Squibb Company (Celgene Corp.)
- 14.5. Gilead Sciences, Inc. (Kite Pharma)
- 14.6. Johnson & Johnson (Janssen Biotech, Inc.)
- 14.7. Merck & Co., Inc.
- 14.8. Novartis AG
- 14.9. Roche Holding AG (F. Hoffmann-La Roche AG)
- 14.10. Seagen, Inc. (Seattle Genetics, Inc.)
- 14.11. Takeda Pharmaceutical Co., Ltd.
- 14.12. Teva Pharmaceutical Industries Ltd.(*LIST NOT EXHAUSTIVE)
- 15. Appendix
- 15.1. About Us and Services
- 15.2. Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
